
https://www.science.org/content/blog-post/compassionate-access-no-good-answer
# Compassionate Access: No Good Answer (November 2013)

## 1. SUMMARY
This 2013 commentary examines the ethical and practical complexities of "compassionate use" programs, which allow terminally ill patients access to investigational drugs before FDA approval. The article highlights the fundamental tension between individual patient needs and the collective good of rigorous clinical research. Companies often hesitate to provide compassionate access because only 6% of early-stage cancer drugs reach market approval, and adverse events during compassionate use could generate negative publicity and regulatory scrutiny.

The central dilemma is that widespread compassionate access could undermine clinical trials by reducing patient enrollment, potentially preventing promising drugs from ever reaching approval. The piece also addresses the methodological challenges: uncontrolled compassionate use generates heterogeneous data from different patient populations, physicians, and treatment protocols, making it difficult to extract meaningful efficacy signals. While the article suggests room for improvement in compassionate access systems, it concludes that there are no ideal solutions given the competing interests of individual patient welfare versus systematic drug development.

## 2. HISTORY
In the decade following this article, compassionate access evolved significantly through both regulatory changes and high-profile cases. The FDA's Expanded Access program became more standardized, with formal guidance issued and streamlined application processes. However, the fundamental tensions identified in 2013 persisted and became more visible.

**Right to Try Legislation:** The most significant policy development was the federal Right to Try Act passed in 2018, allowing terminally ill patients to access unapproved drugs without FDA oversight. Despite the legislation, actual patient access through Right to Try remained limited, as companies retained discretion to deny requests. Most treatments accessed through this pathway were already in late-stage trials, suggesting companies remained cautious about potential risks to their development programs.

**High-Profile Cases:** Several cases brought compassionate access into public consciousness. Josh Hardy's 2014 case, where a young boy received an experimental antiviral treatment after public pressure on Chimerix, highlighted both the potential power of advocacy and the ethical pressures on companies. Similarly, during the Ebola outbreak and later the COVID-19 pandemic, compassionate use became a mechanism for deploying experimental treatments, though often with insufficient data to assess efficacy.

**COVID-19 Impact:** The pandemic created unprecedented demand for compassionate access to remdesivir and other investigational treatments. This surge revealed both the potential scale of compassionate use and its limitations—most COVID-19 compassionate use cases generated anecdotal evidence but little systematic data about efficacy.

**Industry Response:** Pharmaceutical companies developed more sophisticated compassionate access policies, with many establishing formal programs. However, the practical barriers identified in 2013—manufacturing limitations, regulatory concerns, and trial interference—meant that many requests continued to be denied. Data from FDA Expanded Access reports showed gradual increases in annual requests, but the overall numbers remained small compared to clinical trial participation.

**Clinical Research Evolution:** The rise of adaptive trial designs and real-world evidence collection partially addressed some 2013 concerns about data heterogeneity. However, the core tension identified—that uncontrolled access threatens systematic evidence generation—remained unresolved.

## 3. PREDICTIONS
• **Prediction:** "If everyone storms the gates, it's quite true that we won't be able to make sense of many of these new therapies at all."

**Outcome:** Mixed. While mass demand for compassionate access never materialized on the scale feared, the COVID-19 pandemic did create "storming the gates" scenarios where demand for experimental treatments exceeded supply and systematic evaluation. However, the overall number of compassionate use requests remained manageable, suggesting that most patients and physicians continued to prioritize participation in controlled trials when available.

• **Prediction:** Widespread compassionate access would make clinical trials impossible because "drug companies would most likely never get anyone to enroll in them."

**Outcome:** This did not occur. Clinical trial enrollment remained robust, and compassionate access programs did not substantially compete with formal trials. However, this may reflect that companies carefully gate-kept compassionate access to avoid cannibalizing trial enrollment, rather than a fundamental lack of patient interest.

• **Prediction:** Without controlled compassionate use systems, patients would remain "vulnerable to charlatans" seeking unproven treatments.

**Outcome:** Accurate. Even with improved compassionate access systems, patients continued to seek unproven treatments outside regulatory oversight, including stem cell clinics, off-label drug combinations, and international treatment centers offering therapies not approved in their home countries.

• **Prediction:** Improved compassionate access systems were possible but would never reach an "ideal setup."

**Outcome:** Accurate. While regulatory frameworks improved, the fundamental trade-offs between individual access and collective evidence generation persisted. The Right to Try legislation attempted to address this but had limited practical impact due to company discretion and manufacturing constraints.

## 4. INTEREST
**Decile Score: 7**

This article captured a persistent challenge in medical ethics and drug development policy while accurately identifying the structural barriers to compassionate access. Though the specific policy landscape evolved significantly with Right to Try legislation, the core tensions highlighted—between individual patient needs and systematic evidence generation—remain unresolved over a decade later.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20131105-compassionate-access-no-good-answer.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_